Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.14 USD

806.14
3,911,551

-12.79 (-1.56%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

The Zacks Analyst Blog Highlights: Eli Lilly, Qualcomm and Electronic Arts

The Zacks Analyst Blog Highlights: Eli Lilly, Qualcomm and Electronic Arts

Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day

Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day

Benjamin Rains headshot

3 Stocks Immune to the Coronavirus Downturn to Buy Right Now

Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...

Sejuti Banerjea headshot

Another Drug to Fight Coronavirus & 3 Picks

Another drug is being tested to kill the virus (if we can figure out administration on humans).

Why the Earnings Surprise Streak Could Continue for Lilly (LLY)

Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

John Blank headshot

Where Might Our Next 'Heroes' Be? Global Week Ahead

Disastrous jobless figures tarnish the week's econ data. Meanwhile, investors who need returns to meet pension or insurance liabilities are seeking 'dividend heroes,' and Swiss banks might take that role.

Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes

Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.

The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor

The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates

J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.

LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day

LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day

Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis

Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.

Tracey Ryniec headshot

Bull of the Day: Eli Lilly (LLY)

This drug maker is expected to grow earnings by the double digits in 2020.

Sheraz Mian headshot

Top Analyst Reports for Eli Lilly, Charter Communications & Eaton

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Charter Communications (CHTR) and Eaton (ETN).

Benjamin Rains headshot

Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy

Eli Lilly (LLY) stock closed the first quarter above where it started, which was no easy task. So let's dive into why investors might want to buy LLY stock right now...

Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA

Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.

Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Indrajit Bandyopadhyay headshot

3 Drugmakers Still Worth Betting on Amid Coronavirus Woes

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Benjamin Rains headshot

Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus

AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...

Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children

The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.

Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View

Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.

AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic

AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.

Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia

The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.

Indrajit Bandyopadhyay headshot

Pharma, Biotech Players Step Up Efforts Against Coronavirus

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.